(NASDAQ: CGON) Cg Oncology's forecast annual revenue growth rate of 346.67% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.74%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.02%.
Cg Oncology's revenue in 2026 is $5,071,000.On average, 16 Wall Street analysts forecast CGON's revenue for 2026 to be $1,560,742,760, with the lowest CGON revenue forecast at $0, and the highest CGON revenue forecast at $9,660,816,868. On average, 16 Wall Street analysts forecast CGON's revenue for 2027 to be $12,091,677,024, with the lowest CGON revenue forecast at $2,160,960,589, and the highest CGON revenue forecast at $38,975,790,794.
In 2028, CGON is forecast to generate $44,103,000,549 in revenue, with the lowest revenue forecast at $18,420,204,461 and the highest revenue forecast at $71,033,861,631.